Review Article

Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Figure 7

Relative risk with 95% CIs of all interventions from network meta-analysis for adverse events(AEs). Different interventions in the middle block divide the graph into upper and lower triangles; for the lower triangle, the efficacy estimate is the ratio of the column defining treatment to the row defining treatment. In case that the confidence interval does not include 1, if , it favors the row defining treatment. In contrast, if , it favors the column defining treatment. The upper triangle is symmetrical to the lower triangle. The efficacy estimate is the ratio of the row defining treatment to the column defining treatment. The results are mutually reciprocal. Statistically significant results have been applied with italic formatting.